Kyverna Therapeutics Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Encouraged To Join

EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events: Investor Conference Details:     Morgan Stanley Global Healthcare Conference in New York, NY on September 4, 2024 Format: Fireside Chat with Mike Ulz at 11:30 am EDT and host investor meetings Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024 Format: Fireside Chat with Derek Archila at 2:15 pm EDT and host investor meetings Cantor Global Healthcare Conference in New York, NY on September 17, 2024 Format: Fireside Chat with Eric Schmidt at 10:20 am EDT and host investor meetings Investors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative.

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Participate In The Investigation Of Kyverna Therapeutics Inc For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Join The Securities Fraud Investigation Of Kyverna Therapeutics Inc

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Participate In Kyverna Therapeutics Inc's Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Join Kyverna Therapeutics Inc's Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Kyverna Therapeutics Inc's Investors To Join The KYTX Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Kyverna Therapeutics Inc's Shareholders To Join The KYTX Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Kyverna Therapeutics Inc's Stakeholders To Participate In The KYTX Securities Fraud Investigation

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders Of Kyverna Therapeutics Inc Are Welcomed By The Schall Law Firm To Participate In The KYTX Securities Fraud Probe

Kyverna Therapeutics Inc's Stakeholders Are Invited By The Schall Law Firm To Join The KYTX Securities Fraud Investigation

Actively recruiting clinical trials in neurology and rheumatology with KYV-101 No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person Syndrome Received FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia Gravis Reported clinical experience with first KYV-101 patient disease-free at 1 year after treatment EMERYVILLE, Calif. , Aug. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2024.

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

The application was evaluated based on the positive clinical outcomes in patients treated in Germany under the named-patient program The Regenerative Medicine Advanced Therapies designation allows Kyverna to leverage on more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101 EMERYVILLE, Calif. , Aug. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the designation as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from progressive myasthenia gravis.

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc's Stakeholders Are Encouraged By The Schall Law Firm To Participate In The KYTX Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Kyverna Therapeutics Inc's Stakeholders To Join In The KYTX Securities Fraud Probe

The Schall Law Firm Invites Stakeholders Of Kyverna Therapeutics Inc To Participate In The KYTX Securities Fraud Investigation

The Schall Law Firm Invites Stakeholders Of Kyverna Therapeutics Inc To Join The KYTX Securities Fraud Probe

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Welcomes Stakeholders Of Kyverna Therapeutics Inc To Join The Kytx Securities Fraud Probe

LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Welcomes Stakeholders Of Kyverna Therapeutics Inc To Join The KYTX Securities Fraud Probe

LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Kyverna Therapeutics Inc Investors To Participate In The Securities Fraud Investigation Into KYTX

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc Investors Are Invited By The Schall Law Firm To Participate In The KYTX Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Kyverna Therapeutics Inc Are Welcomed By The Schall Law Firm To Join The KYTX Securities Fraud Probe

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rivian Automotive, Inc. ("Rivian" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Kyverna Therapeutics Inc Investors Are Invited By The Schall Law Firm To Participate In The Securities Fraud Investigation Into KYTX

The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option The Regenerative Medicine Advanced Therapies designation will allow Kyverna to receive expert guidance on efficient drug development and use of surrogate endpoints from senior FDA officials EMERYVILLE, Calif. , July 15, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the designation as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from refractory stiff-person syndrome.

News for Kyverna Therapeutics Inc Stock (KYTX)